Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy
Brief Summary: The purpose of this study is to determine whether, in patients with chronic proteinuric nephropathy and dyslipidemia, ezetimibe-simvastatin combined therapy is more effective than statin alone to achieve the optimum lipid control, and if this translates to an improvement of the markers of vascular damage. Thirty hypertensive patients in stable therapy with RAS inhibitors, with low-density lipoprotein (LDL) cholesterol superior to 100 mg/ml, are treated with three different hypolipidemic regimens: Simvastatin alone (40 mg/day) or ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day).


Options:
A: Arm Label: Pooled subjects who received ezetimibe with simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe with simvastatin | Arm Label: Pooled subjects who received simvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: ezetimibe with simvastatin; Assigned to Arm(s): Pooled subjects who received ezetimibe with simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): Pooled subjects who received simvastatin monotherapy
B: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Placebo QM; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Ezetimibe (Q2W); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Ezetimibe (QM); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Evolocumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Evolocumab QM; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM) | Intervention Type: BIOLOGICAL; Name: Placebo to Evolocumab; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM), Placebo Q2W, Placebo QM | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM, Placebo Q2W, Placebo QM
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: EZE/simvastatin | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: EZE/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: EZE/simvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EZE/simvastatin; Assigned to Arm(s): 3
D: Arm Label: EZ/Simva 10/40 mg; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): EZ/Simva 10/40 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo

Answer: C